Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | TDO2 | P48775 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7235653 | 1.00 | IDO1 (0.38) | IDO1TDO2SLC6A2SLC6A4 | |
| SCHEMBL3159928 | 0.80 | SLC6A4 (0.43) | IDO1TDO2SLC6A2SLC6A4 | |
| SCHEMBL10488435 | 0.80 | CYP2A6 (0.32) | SLC6A2SLC6A4 | |
| SCHEMBL14889775 | 0.80 | ESR1 (0.37) | IDO1TDO2SLC6A2 | |
| SCHEMBL3784692 | 0.80 | CHRNA7 (0.39) | SLC6A2SLC6A4 | |
| SCHEMBL3687682 | 0.79 | IDO1 (0.44) | IDO1SLC6A2SLC6A4 | |
| SCHEMBL151181 | 0.79 | IDO1 (0.44) | IDO1SLC6A2SLC6A4 | |
| SCHEMBL333671 | 0.77 | CA12 (0.41) | — | |
| SCHEMBL7867600 | 0.77 | EPHX1 (0.41) | IDO1 | |
| SCHEMBL14889733 | 0.76 | LTA4H (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6566538-B1 | Preparation of 5-(aryloxymethyl)-g-butyrolactone derivatives | MILLENNIUM PHARMACEUTICALS, INC. | 2003-05-20 | — | — | US | disclosed |
| EP-1094805-A4 | SUBSTITUTED OXYGEN ALICYCLIC COMPOUNDS, INCLUDING METHODS FOR SYNTHESIS THEREOF | MILLENNIUM PHARM INC (US) | 2002-08-28 | — | — | EP | disclosed |
| US-6433197-B1 | REACTING ARYLHYDROXY COMPOUND AND AN EPOXY COMPOUND TO FORM AN EPOXY-ARYL ETHER; REACTING EPOXY-ARYL ETHER WITH ACTIVE METHYLENE COMPOUND TO FORM A LACTONE; REDUCING TO PROVIDE HYDROXY-SUBSTITUTED TETRAHYDROFURAN | MILLENNIUM PHARMACEUTICALS, INC. | 2002-08-13 | — | — | US | disclosed |
| EP-1115702-A4 | SUBSTITUTED NITROGEN AND SULFUR ALICYCLIC COMPOUNDS, INCLUDING METHODS FOR SYNTHESIS THEREOF | MILLENNIUM PHARM INC (US) | 2002-04-17 | — | — | EP | disclosed |
| US-20020040154-A1 | Substituted oxygen alicyclic compounds, including methods for synthesis thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2002-04-04 | — | — | US | disclosed |
| US-6306895-B1 | PREPARATION OF CYCLIC OXYGEN COMPOUNDS, INCLUDING 2,5-DISUBSTITUTED TETAHYDROFURANS, 2,6-DISUBSTITUTED TETRAHYDROPYRANS, 2,7-DISUBSTITUTED OXEPANES AND 2,8-OXOCANES. THE INVENTION ALSO PROVIDES NEW CYCLIC OXYGEN COMPOUNDS AND | MILLENIUM PHARMACEUTICALS, INC. | 2001-10-23 | — | — | US | disclosed |
| EP-1115702-A1 | SUBSTITUTED NITROGEN AND SULFUR ALICYCLIC COMPOUNDS, INCLUDING METHODS FOR SYNTHESIS THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2001-07-18 | — | — | EP | disclosed |
| EP-1094805-A1 | SUBSTITUTED OXYGEN ALICYCLIC COMPOUNDS, INCLUDING METHODS FOR SYNTHESIS THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2001-05-02 | — | — | EP | disclosed |
| WO-2000001381-A1 | SUBSTITUTED OXYGEN ALICYCLIC COMPOUNDS, INCLUDING METHODS FOR SYNTHESIS THEREOF | LEUKOSITE, INC. (US) | 2000-01-13 | — | — | WO | disclosed |
| WO-2000001670-A1 | SUBSTITUTED NITROGEN AND SULFUR ALICYCLIC COMPOUNDS, INCLUDING METHODS FOR SYNTHESIS THEREOF | LEUKOSITE, INC. (US) | 2000-01-13 | — | — | WO | disclosed |
| US-3953604-A | INHALATION, ANTI-ASTHMA | MILES LABORATORIES, INC. (US) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040154-A1 | Substituted oxygen alicyclic compounds, including methods for synthesis thereof | OXER1, COX6C, MT-CO2 | IDO1 279/4885TDO2 56/4885SLC6A2 4075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.